Knight Therapeutics Inc. (TSE:GUD – Get Free Report) insider Sime Armoyan sold 300,000 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of C$6.13, for a total value of C$1,839,000.00.
Knight Therapeutics Stock Down 1.8 %
Knight Therapeutics stock opened at C$5.91 on Tuesday. The business has a fifty day moving average of C$5.73 and a two-hundred day moving average of C$5.69. The company has a quick ratio of 1.79, a current ratio of 3.41 and a debt-to-equity ratio of 7.62. The firm has a market cap of C$598.15 million, a P/E ratio of -29.55, a P/E/G ratio of -1,013.50 and a beta of 0.48. Knight Therapeutics Inc. has a twelve month low of C$4.35 and a twelve month high of C$6.23.
Knight Therapeutics (TSE:GUD – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported C($0.02) EPS for the quarter, missing the consensus estimate of C$0.03 by C($0.05). Knight Therapeutics had a negative net margin of 6.28% and a negative return on equity of 2.70%. The business had revenue of C$95.57 million for the quarter, compared to analysts’ expectations of C$89.83 million. On average, analysts forecast that Knight Therapeutics Inc. will post 0.1077501 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Analysis on Knight Therapeutics
About Knight Therapeutics
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Read More
- Five stocks we like better than Knight Therapeutics
- How to Evaluate a Stock Before BuyingÂ
- The Average 401k Balance by Age Explained
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- What is the Shanghai Stock Exchange Composite Index?
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.